Two groups of infant rhesus macaques received one of two potential COVID-19 vaccines, which were shown to elicit high levels of neutralising antibodies.
List view / Grid view
US National Institute of Allergy and Infectious Diseases (NIAID)
Although a cure for HIV continues to elude scientists, strategies to control the virus and immunise people are developing at rapid pace. Here, Drug Target Review’s Victoria Rees discusses why researchers are focusing on antibodies as approaches to combat HIV and highlights recent findings from two pre-clinical studies into how…
Researchers have revealed that T cells in blood samples from people who recovered from COVID-19 responded to SARS-CoV-2 variants.
A new vaccine formulated with nanoparticles protected animal models from a variety of seasonal and pandemic influenza strains.
The National Institute of Health envisions a plan for managing tuberculosis in the 21st century. Included in this proposal is targeting host proteins as an add-on therapy to antibiotics. Infectious disease biologists are focusing on this strategy and it is a topic of active research. Recently, a multinational research team…
The global network of centers will investigate where pathogens emerge and how they adapt to cause disease in humans, in the hopes of increasing our preparedness for future disease outbreaks.
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
A vaccine currently in Phase I clinical trials was effective at inducing immune responses against SARS-CoV-2 in mice and rhesus macaques.
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
The US National Institute of Allergy and Infectious Diseases (NIAID) plan outlines four research priorities, including furthering understanding of SARS-CoV-2 viral transmission and pathogenesis and development of animal models.
The CEPI has announced three respective projects with Inovio, the University of Queensland and Moderna, to develop a vaccine for the novel coronavirus, nCoV-2019.